Skip to main content

A New Approach for Skin-Derived Precursors to Ameliorate Skin Photodamage Through Activation of Nrf2 Signaling Pathway

Buy Article:

$68.00 + tax (Refund Policy)

Background: Skin photodamage exhibits poorly clinical efficacy and so far has rarely satisfactory treatments. Ultraviolet (UV)-induced overproduction of reactive oxygen species (ROS), NF-E2-related factor 2 (Nrf2) inactivation and Nrf2/antioxidant response elements (ARE) signaling pathway blockage play important roles in skin photodamage pathogenesis. Skin-derived precursor cells (SKPs), a population of dermal stem cells, are predominant over wound repair and skin regeneration.

Objective: To hypothesize that SKPs are useful in skin photodamage by Nrf2 activation.

Methods: Published papers on skin photodamage and SKPs were collected and reviewed. Besides, the findings from our preliminary experiment were reported in this article.

Results: It has been confirmed that stem cells could participate in tissue repair via activating Nrf2 and Nrf2/ARE signal transduction pathway. Furthermore, our previous and current outcomes revealed that SKPs could ameliorate UVB-induced apoptosis or damage and significantly up-regulate Nrf2 expression after UV irradiation.

Conclusion: Together the above data, we speculate that SKPs may be good candidates for control of skin photodamage through activating Nrf2 and its signaling pathway. These would provide a new approach for resisting skin photodamage.

Keywords: NF-E2-related factor 2 (Nrf2); Skin photodamage; oxidative stress; reactive oxygen species (ROS); skin-derived precursor cells (SKPs); stem cells; ultraviolet (UV)

Document Type: Research Article

Publication date: 01 April 2017

More about this publication?
  • In recent years a breakthrough has occurred in our understanding of the molecular pathomechanisms of human diseases whereby most of our diseases are related to intra and intercellular communication disorders. The concept of signal transduction therapy has got into the front line of modern drug research, and a multidisciplinary approach is being used to identify and treat signaling disorders.

    The aim of this journal is to publish timely in-depth reviews as well as original papers in the field of signal transduction therapy. Thematic issues will also be published to cover selected areas of signal transduction therapy. Coverage of the field will include genomics, proteomics, medicinal chemistry and the relevant diseases involved in signaling e.g. cancer, neurodegenerative and inflammatory diseases.

    Current Signal Transduction Therapy is an essential journal for all involved in drug design and discovery.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content